ASHEVILLE, N.C., June 23, 2015 /PRNewswire/ -- The board of directors of Genova Diagnostics is pleased to announce that it has appointed Christopher S. Smith to be the Company’s next president and chief executive officer, effective Monday, June 22, 2015. Mr. Smith has served as vice-president of sales and marketing since joining Genova in February 2006. He has been responsible for developing the Company’s industry-leading educational marketing and consultative selling growth model, which has yielded consistent double-digit revenue growth over his tenure. He received both his bachelors in biochemistry and masters in business administration degrees from Texas A&M University.
Current president and chief executive officer, Ted Hull, announced his retirement in March and has been working with the board to identify his successor. Mr. Hull has been with Genova since January 2000 and served in his current role since December 2003. Over the last twelve years, Mr. Hull is credited with leading the Company through significant profitable growth and with developing and executing the strategy that has seen the company grow into a world leader in applying a systems-based testing approach to diagnosing and treating complex chronic illnesses.
“I am thrilled that the board has appointed Chris to become the next CEO of Genova Diagnostics. His background in laboratory operations, success in building new markets and his experience with Genova make him the ideal person to take Genova forward. I look forward to continuing to support Chris and Genova as an investor and board member,” said Mr. Hull.
Genova Diagnostics is a privately held company, majority owned by Levine Leichtman Capital Partners, a private investment firm headquartered in Beverly Hills, California. “We invested in Genova alongside management in November 2013 because of its outstanding track record as an innovator and leading company in the rapidly growing market of systems-based diagnostic testing for complex chronic disease. We are excited to have Chris take over the reins and continue the growth. We would also like to thank Ted for his role in building Genova and look forward to continuing to work with him as an investor and board member,” said Lauren Leichtman, CEO of Levine Leichtman Capital Partners.
“I would like to thank the board of Genova Diagnostics for giving me the opportunity to lead one of the most innovative and exciting companies in the specialty lab testing market. I look forward to continuing to work with the Genova team and LLCP to achieve the mission of Genova Diagnostics to be the best provider of comprehensive and innovative clinical laboratory services for the prevention, diagnosis and treatment of complex chronic disease,” said Mr. Smith.
About Genova Diagnostics, Inc.
Established in 1986, Genova Diagnostics is a leading company in applying a systems-based approach in clinical laboratory testing for the diagnosis, treatment and prevention of complex chronic disease. Systems-based testing is offered in a number of clinical areas, including gastrointestinal, nutritional, immunologic and endocrine, addressing a range of complex chronic conditions, including pre-diabetes, cardiovascular disease, nutritional deficiencies, hormone imbalances, depression, autoimmune disease, allergies, and irritable bowel syndrome. Genova has developed a lab industry leading commercial system for building markets for innovative testing by partnering clinician education with field-based consultative selling approach. More information about Genova Diagnostics is available at www.gdx.net.
About Levine Leichtman Capital Partners
Levine Leichtman Capital Partners is an independent investment firm that invests in middle market companies located in the United States and Europe. LLCP has managed approximately $7.0 billion of institutional capital since its inception on behalf of itself and its worldwide network of investors. These investors include state and corporate pension plans, insurance companies, fund of funds, family offices, foundations and endowments. Established in California in 1984 by Arthur E. Levine and Lauren B. Leichtman, the Firm has expanded geographically with offices in Los Angeles, Dallas, Chicago, New York, London, and The Hague. The Firm has a proven business philosophy of investing alongside entrepreneurs who believe in their company’s growth and want substantial equity ownership.
Contact:
Jennifer Gillen, E-mail: IR-PR@GDx.net, Phone: 800-522-4762
Logo - http://photos.prnewswire.com/prnh/20150623/225046LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genova-diagnostics-announces-new-ceo-300103441.html
SOURCE Genova Diagnostics, Inc.
Help employers find you! Check out all the jobs and post your resume.
